Trial Profile
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Aldafermin (Primary)
- Indications Primary sclerosing cholangitis
- Focus Therapeutic Use
- Sponsors NGM Biopharmaceuticals
- 29 Aug 2020 Results of pooled analysis assessing plasma levels of PRO-C3X by using data from two phase II studies presented at The International Liver Congress 2020
- 29 Aug 2020 Results presented at The International Liver Congress 2020
- 08 Nov 2018 Results published in the Journal of Hepatology